Generic Drugs Conference Concludes in Riyadh Under the Theme "Empowering Local Pharmaceutical Manufacturing"

The Saudi Food and Drug Authority (SFDA) successfully concluded the Generic Drugs Conference, themed "Empowering Local Pharmaceutical Manufacturing," held at its headquarters in Riyadh on Tuesday. The conference was attended by the SFDA CEO, H.E. Dr. Hisham S. Aljadhey, alongside representatives from regulatory bodies, pharmaceutical companies, healthcare providers, and a distinguished group of investors and academic experts.

The conference agenda featured scientific sessions and panel discussions highlighting the future of the pharmaceutical sector amidst rapid technological advancements that have a direct impact on the global healthcare and pharmaceutical landscape. Conversations focused on global best practices to align the industry with the strategic objectives of Saudi Vision 2030.

The conference highlighted significant investment opportunities within the Kingdom, particularly the increasing government incentives designed to support local and foreign investors. Such efforts are instrumental in solidifying Saudi Arabia’s position as a cornerstone of the global pharmaceutical industry.

The conference addressed several pivotal themes, including investment opportunities and government incentives, as well as the role of hospital drug lists and procurement policies in promoting the use of generic drugs according to approved standards. Additionally, participants emphasized the importance of integrated efforts among regulatory authorities to build public and clinical trust in generic drugs.

The closing session highlighted the importance of continued collaboration between the SFDA, the pharmaceutical industry, and healthcare providers. The goal is to foster innovation, expedite patient access to essential medications, and leverage industry feedback to develop regulations that ensure the sustainability of quality and safety standards.

By presenting key investment opportunities, the conference highlighted the pharmaceutical sector's role in sustainable healthcare. It further solidified the SFDA's reputation as a globally recognized scientific authority and highlighted its strategic role in diversifying the national economy and advancing the Kingdom's healthcare and pharmaceutical ecosystems.